General
Preferred name
TRIMETAZIDINE
Synonyms
TRIMETAZIDINE DIHYDROCHLORIDE ()
Kyurinett ()
Yoshimilon ()
Vastarel F ()
Trimetazidine (dihydrochloride) ()
Yoshimilon, Kyurinett, Vastarel F ()
Trimetazidine (hydrochloride) ()
Trimetazidine hydrochloride ()
NSC-759317 ()
Trimetazidine di-hcl ()
Trimetazidine hcl ()
Trimethazidine dihydrochloride ()
Vastarel MR ()
Trimetazidina ()
Vastarel ()
Dilatan ()
Trimetazidine-d8 (hydrochloride) ()
P&D ID
PD009144
CAS
5011-34-7
13171-25-0
127881-54-3
1219795-37-5
Tags
available
drug candidate
drug
First approval
1978
Drug Status
approved
investigational
Max Phase
3.0
Drug indication
Cardiovascular disease
Hepatocellular carcinoma
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Trimetazidine dihydrochloride is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit ¦Â-oxidation of free fatty acid (FFA). Trimetazidine dihydrochloride is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine dihydrochloride triggers autophagy. Trimetazidine dihydrochloride is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].
PRICE
29
DESCRIPTION
Trimetazidine is a selective long chain 3-ketoyl coenzyme A thiolase inhibitor with an IC50 of 75 nM, which can inhibit ¦Â-oxidation of free fatty acid (FFA). Trimetazidine is an effective antianginal agent and a cytoprotective agent, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. Trimetazidine triggers autophagy. Trimetazidine is also a 3-hydroxyacyl-CoA dehydrogenase (HADHA) inhibitor[1][2][3][4].
DESCRIPTION
Trimetazidine dihydrochloride (Vastarel F) can improve myocardial glucose utilization by inhibiting fatty acid metabolism. Trimetazidine is the first cytoprotective anti-ischemic agent, also used as a vasodilator in ischemic heart disease or angina.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Trimetazidine is a selective long chain 3-ketoyl CoA thiolase inhibitor. Trimetazidine is an effective antianginal agent and a cytoprotective drug, has anti-oxidant, anti-inflammatory, antinociceptive and gastroprotective properties. It is a piperazine derivative indicated as an adjunct therapy in symptomatic treatment of stable angina pectoris.
(Enamine Bioactive Compounds)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
19
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
Mcule NIBR MoA Box Subset
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
48
Molecular Weight
266.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
2
Aromatic Ring Count
1
cLogP
1.12
TPSA
42.96
Fraction CSP3
0.57
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Metabolism
Member status
virtual
MOA
3-Ketoacyl-CoA Thiolase (3-KAT) Inhibitors
3-ketoacyl CoA thiolase inhibitor
Indication
angina pectoris
Target
ACAA2
FAO
mitochondrial long-chain 3-ketoacyl thiolase
Source data
